Israel
· Delayed Price · Currency is ILS · Price in ILABio-View Statistics
Total Valuation
Bio-View has a market cap or net worth of ILS 35.97 million. The enterprise value is 21.98 million.
| Market Cap | 35.97M |
| Enterprise Value | 21.98M |
Important Dates
The next estimated earnings date is Thursday, November 21, 2024.
| Earnings Date | Nov 21, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Bio-View has 130.33 million shares outstanding. The number of shares has decreased by -28.39% in one year.
| Shares Outstanding | 130.33M |
| Shares Change (YoY) | -28.39% |
| Shares Change (QoQ) | -6.19% |
| Owned by Insiders (%) | 52.59% |
| Owned by Institutions (%) | 4.21% |
| Float | 55.22M |
Valuation Ratios
The trailing PE ratio is 45.27.
| PE Ratio | 45.27 |
| Forward PE | n/a |
| PS Ratio | 1.08 |
| PB Ratio | 1.26 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.26, with an EV/FCF ratio of -16.78.
| EV / Earnings | 24.78 |
| EV / Sales | 0.64 |
| EV / EBITDA | 11.26 |
| EV / EBIT | 244.18 |
| EV / FCF | -16.78 |
Financial Position
The company has a current ratio of 2.89, with a Debt / Equity ratio of 9.58.
| Current Ratio | 2.89 |
| Quick Ratio | 2.09 |
| Debt / Equity | 9.58 |
| Debt / EBITDA | 1.44 |
| Debt / FCF | -2.14 |
| Interest Coverage | 0.26 |
Financial Efficiency
Return on equity (ROE) is 3.06% and return on invested capital (ROIC) is 0.17%.
| Return on Equity (ROE) | 3.06% |
| Return on Assets (ROA) | 0.13% |
| Return on Capital (ROIC) | 0.17% |
| Revenue Per Employee | 1.04M |
| Profits Per Employee | 26,879 |
| Employee Count | 33 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 1.76 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.99% in the last 52 weeks. The beta is 0.37, so Bio-View's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | -99.99% |
| 50-Day Moving Average | 25.49 |
| 200-Day Moving Average | 24,265.33 |
| Relative Strength Index (RSI) | 57.80 |
| Average Volume (20 Days) | 97,827 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bio-View had revenue of ILS 34.34 million and earned 887,000 in profits. Earnings per share was 0.01.
| Revenue | 34.34M |
| Gross Profit | 22.28M |
| Operating Income | 90,000 |
| Pretax Income | 1.40M |
| Net Income | 887,000 |
| EBITDA | 452,000 |
| EBIT | 90,000 |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 16.80 million in cash and 2.80 million in debt, giving a net cash position of 13.99 million or 0.11 per share.
| Cash & Cash Equivalents | 16.80M |
| Total Debt | 2.80M |
| Net Cash | 13.99M |
| Net Cash Per Share | 0.11 |
| Equity (Book Value) | 29.27M |
| Book Value Per Share | 0.22 |
| Working Capital | 22.08M |
Cash Flow
In the last 12 months, operating cash flow was -1.25 million and capital expenditures -60,000, giving a free cash flow of -1.31 million.
| Operating Cash Flow | -1.25M |
| Capital Expenditures | -60,000 |
| Free Cash Flow | -1.31M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 64.86%, with operating and profit margins of 0.26% and 2.58%.
| Gross Margin | 64.86% |
| Operating Margin | 0.26% |
| Pretax Margin | 4.09% |
| Profit Margin | 2.58% |
| EBITDA Margin | 1.32% |
| EBIT Margin | 0.26% |
| FCF Margin | -3.81% |
Dividends & Yields
Bio-View does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 28.39% |
| Shareholder Yield | 28.39% |
| Earnings Yield | 2.21% |
| FCF Yield | -3.64% |
Stock Splits
The last stock split was on December 24, 2023. It was a forward split with a ratio of 10.
| Last Split Date | Dec 24, 2023 |
| Split Type | Forward |
| Split Ratio | 10 |